Lilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...

The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...

Early CDMO engagement can be valuable, particularly when it helps development teams understand technical requirements, dependencies, timelines, and potential risks. But engaging early does not mean ...

RFK Jr. has given notice that the agency won’t take enforcement action on six peptides that controversially won a contested ...

The fledgling startup has $90 million to develop a pipeline of drugs, led by a Charcot-Marie-Tooth disease medicine, that ...

The drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become ...

The latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely ...

The plan builds on recent FDA moves to speed "personalized" treatments by offering an approval framework for therapies ...

The highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher ...

The buyout hands Ferring rights to a technology capable of simplifying the lengthy and burdensome process of in vitro ...